[
  {
    "ts": null,
    "headline": "McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week",
    "summary": "Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over the next week. This past week featured results from four companies in the “Magnificent Seven,” plus President Trump’s reciprocal tariff deadline and a weak July jobs report.",
    "url": "https://finnhub.io/api/news?id=20f37e84e3ea0fbc2542950aab83c2d82c3e92cb8fff948d49d35fdc27977af2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754080716,
      "headline": "McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week",
      "id": 136183225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over the next week. This past week featured results from four companies in the “Magnificent Seven,” plus President Trump’s reciprocal tariff deadline and a weak July jobs report.",
      "url": "https://finnhub.io/api/news?id=20f37e84e3ea0fbc2542950aab83c2d82c3e92cb8fff948d49d35fdc27977af2"
    }
  },
  {
    "ts": null,
    "headline": "KBRA Assigns Preliminary Ratings to VRTX 2025-HQ",
    "summary": "NEW YORK, August 01, 2025--KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower’s fee simple interest in Vertex HQ , two 15-story, C",
    "url": "https://finnhub.io/api/news?id=e4133371c8a6eea7101c1f4feb1e06ae10257cb4025a2e2e3d8d1a39c542fd0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754068440,
      "headline": "KBRA Assigns Preliminary Ratings to VRTX 2025-HQ",
      "id": 136183440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "NEW YORK, August 01, 2025--KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower’s fee simple interest in Vertex HQ , two 15-story, C",
      "url": "https://finnhub.io/api/news?id=e4133371c8a6eea7101c1f4feb1e06ae10257cb4025a2e2e3d8d1a39c542fd0a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=f2118f0b78a0e80194851f65ef69006de00cb10c5d48646ec4687a82a68b0ccb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754066220,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "id": 136253500,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=f2118f0b78a0e80194851f65ef69006de00cb10c5d48646ec4687a82a68b0ccb"
    }
  },
  {
    "ts": null,
    "headline": "Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200",
    "summary": "Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out why FOLD stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=2106b810c7484fc1b68926270e492e86e07027570c70f795cb29733d950d87a7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754064284,
      "headline": "Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200",
      "id": 136178285,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184958576/image_2184958576.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out why FOLD stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=2106b810c7484fc1b68926270e492e86e07027570c70f795cb29733d950d87a7"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now",
    "summary": "These growth stocks have plenty of room to run.",
    "url": "https://finnhub.io/api/news?id=ccb07f197dc27f091f54a8895ceb3396d079280ce81af29d591af352c0e8148b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754044200,
      "headline": "2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now",
      "id": 136165533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "These growth stocks have plenty of room to run.",
      "url": "https://finnhub.io/api/news?id=ccb07f197dc27f091f54a8895ceb3396d079280ce81af29d591af352c0e8148b"
    }
  }
]